LncRNA MALAT1 Promotes Cancer Metastasis in Osteosarcoma via Activation of the PI3K-Akt Signaling Pathway
Open Access
- 27 November 2018
- journal article
- research article
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 51 (3), 1313-1326
- https://doi.org/10.1159/000495550
Abstract
Background/Aims: LncRNAs have been reported to be vital regulators of the progression of osteosarcoma, although the underlying mechanisms are not completely understood. Methods: The levels of MALAT1 and miR-129-5p expression were measured using qRT-PCR. Cell growth was determined using the CCK-8 and colony formation assays. Cell migration and invasion were detected using the wound healing and Transwell invasion assays, respectively. Tumor growth was determined with a xenograft model. Results: MALAT1 was significantly up-regulated in osteosarcoma tissues compared with adjacent non-tumor soft tissues. Overexpression of MALAT1 promoted osteosarcoma cell proliferation, migration, and invasion in vitro and enhanced tumor growth in a tumor xenograft mouse model. MALAT1 promoted osteosarcoma progression by modulating stem cell-like properties. Moreover, rescue experiment and luciferase reporter assay results indicated that MALAT1 modulates RET expression by sponging miR-129-5p in osteosarcomas. Furthermore, MALAT1 augmented the expression of downstream proteins of the RET-Akt pathway. MALAT1 was consistently significantly increased in osteosarcoma tissues and MALAT1 expression was positively correlated with tumor size and metastasis. High expression of MALAT1 was significantly associated with poor outcomes in patients with osteosarcomas. MALAT1 expression was positively related to RET and negatively related to miR-129-5p in osteosarcoma samples and xenograft tumors. MALAT1 functioned as an oncogenic lncRNA in osteosarcomas and was as an independent prognostic indicator. Conclusion: Our data revealed for the first time that MALAT1 increases stem cell-like properties by up-regulating RET via sponging miR-129-5p, and thus activates the PI3K-Akt signaling pathway and provides potential therapeutic targets for osteosarcoma treatment.Keywords
This publication has 22 references indexed in Scilit:
- Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessJournal of Clinical Oncology, 2015
- EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC modelsMedical Oncology, 2015
- Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceCancer Letters, 2015
- Epigenetic Regulation of the lncRNA MEG3 and Its Target c-MET in Pancreatic Neuroendocrine TumorsMolecular Endocrinology, 2015
- Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signatureNature Communications, 2014
- Differential regulation of non-protein coding RNAs from Prader-Willi Syndrome locusScientific Reports, 2014
- Osteocytes Serve as a Progenitor Cell of OsteosarcomaJournal of Cellular Biochemistry, 2014
- P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expressionCell Death & Disease, 2014
- Long noncoding RNAs and the genetics of cancerBritish Journal of Cancer, 2013
- Modeling human osteosarcoma in mice through 3AB‐OS cancer stem cell xenograftsJournal of Cellular Biochemistry, 2012